218 related articles for article (PubMed ID: 26378761)
1. Cutaneous manifestations and gastrointestinal disorders: Report of two emblematic cases.
Carlesimo M; Abruzzese C; Narcisi A; Margagnoni G; Zerboni G; Purchiaroni F; Pagnini C; Di Giulio E; Corleto VD
Clin Ter; 2015; 166(4):e269-72. PubMed ID: 26378761
[TBL] [Abstract][Full Text] [Related]
2. [Cutaneous and mucosal manifestations of inflammatory bowel diseases].
Károlyi Z; Erós N; Ujszászy L; Nagy G
Orv Hetil; 2000 Jun; 141(25):1391-5. PubMed ID: 10934882
[TBL] [Abstract][Full Text] [Related]
3. Dermatologic manifestations in inflammatory bowel disease in Tunisia.
Mebazaa A; Aounallah A; Naija N; Cheikh Rouhou R; Kallel L; El Euch D; Boubaker J; Mokni M; Filali A; Ben Osman A
Tunis Med; 2012 Mar; 90(3):252-7. PubMed ID: 22481199
[TBL] [Abstract][Full Text] [Related]
4. [Cutaneous manifestations in inflammatory bowel disease].
Chavez-Álvarez S; Gómez-Flores M; Ocampo-Candiani J
Gac Med Mex; 2016; 152(5):622-630. PubMed ID: 27792697
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous manifestations associated with chronic inflammatory bowel disease].
Farhi D; Cosnes J; Aractingi S; Khosrotehrani K
Ann Dermatol Venereol; 2009 Nov; 136(11):828-33; 826-7, 834-5. PubMed ID: 19917440
[No Abstract] [Full Text] [Related]
6. Inflammatory Cutaneous Lesions in Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab: An ECCO CONFER Multicentre Case Series.
Phillips FM; Verstockt B; Sebastian S; Ribaldone D; Vavricka S; Katsanos K; Slattery E; de Suray N; Flores C; Fries W; Vincenzi F; Capoferro E; Bachmann O; Kopylov U
J Crohns Colitis; 2020 Oct; 14(10):1488-1493. PubMed ID: 32318735
[TBL] [Abstract][Full Text] [Related]
7. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease.
Ampuero J; Rojas-Feria M; Castro-Fernández M; Cano C; Romero-Gómez M
J Gastroenterol Hepatol; 2014 Feb; 29(2):291-5. PubMed ID: 23927379
[TBL] [Abstract][Full Text] [Related]
9. Concomitant occurrence of pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease.
Goldberg I; Finkel O; Gat A; Sprecher E; de Morentin HM
Isr Med Assoc J; 2014 Mar; 16(3):168-70. PubMed ID: 24761705
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous manifestations of Crohn's disease, its spectrum, and its pathogenesis: intracellular consensus bacterial 16S rRNA is associated with the gastrointestinal but not the cutaneous manifestations of Crohn's disease.
Crowson AN; Nuovo GJ; Mihm MC; Magro C
Hum Pathol; 2003 Nov; 34(11):1185-92. PubMed ID: 14652821
[TBL] [Abstract][Full Text] [Related]
11. Giant cells in pyoderma gangrenosum.
Sanders S; Tahan SR; Kwan T; Magro CM
J Cutan Pathol; 2001 Feb; 28(2):97-100. PubMed ID: 11168758
[TBL] [Abstract][Full Text] [Related]
12. Review article: skin complications associated with inflammatory bowel disease.
Tavarela Veloso F
Aliment Pharmacol Ther; 2004 Oct; 20 Suppl 4():50-3. PubMed ID: 15352894
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy.
Marzano AV; Borghi A; Stadnicki A; Crosti C; Cugno M
Inflamm Bowel Dis; 2014 Jan; 20(1):213-27. PubMed ID: 24105394
[TBL] [Abstract][Full Text] [Related]
14. Pyoderma gangrenosum as a first presentation of inflammatory bowel disease.
Shahid S; Myszor M; De Silva A
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25385558
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous manifestations of Crohn's disease.
Burgdorf W
J Am Acad Dermatol; 1981 Dec; 5(6):689-95. PubMed ID: 6459345
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations in inflammatory bowel disease.
Tromm A; May D; Almus E; Voigt E; Greving I; Schwegler U; Griga T
Z Gastroenterol; 2001 Feb; 39(2):137-44. PubMed ID: 11253504
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations of pyoderma gangrenosum associated with inflammatory bowel disease.
Menachem Y; Gotsman I
Isr Med Assoc J; 2004 Feb; 6(2):88-90. PubMed ID: 14986464
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and treatment of inflammatory bowel disease.
Taylor S; Lobo AJ
Practitioner; 2016; 260(1795):19-23. PubMed ID: 28994554
[TBL] [Abstract][Full Text] [Related]
19. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.
Weizman A; Huang B; Berel D; Targan SR; Dubinsky M; Fleshner P; Ippoliti A; Kaur M; Panikkath D; Brant S; Oikonomou I; Duerr R; Rioux J; Silverberg M; Rotter JI; Vasiliauskas E; Haritunians T; Shih D; Li D; Melmed GY; McGovern DP
Inflamm Bowel Dis; 2014 Mar; 20(3):525-33. PubMed ID: 24487271
[TBL] [Abstract][Full Text] [Related]
20. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
Wang J; Prenner J; Wang W; Sakuraba A; Hyman N; Dalal S; Hurst R; Cohen RD; Umanskiy K; Shogan BD; Alpert L; Rubin DT; Colwell J; Pekow J
Aliment Pharmacol Ther; 2020 Jun; 51(12):1365-1372. PubMed ID: 32383278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
